Dsuvia sufentnail nanotabs and storage
Ended Definitive Contract Awarded Last action
- Contract number
- W81XWH20C0133
- Awardee
-
Acelrx Pharmaceuticals, Inc. UEI RS3UJNCL6YG1
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $935,237
Award facts
- Opportunity
-
- Brand Name DSUVIA National Stock Number (NSN) 6505-01-678-1097 Sufentnail NanoTabs Solicitation · W81XWH20R0095 · Posted Aug 19, 2020
- Brand Name DSUVIA National Stock Number (NSN) 6505-01-678-1097 Sufentnail NanoTabs Award Notice · Posted Sep 21, 2020
- Contract value 26% obligated
-
- $935,237.20 Current, with exercised options
- $3,570,235.20 Potential, with all options
- Completion date 100% complete
-
- Current, with exercised options
- Potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Competed under SAP · 2 offers Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Redwood City, CA 94063, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Change Order | -$46 | |
| Supplemental Agreement for work within scope | $3,702 | |
| Supplemental Agreement for work within scope | $7,214 | |
| Original award | $924,368 |
About this award
Acelrx Pharmaceuticals, Inc., doing business as A Development Stage Company, was awarded a definitive contract valued at three million five hundred seventy thousand two hundred thirty-five dollars and twenty cents ($3,570,235.20) by the Defense Health Agency of the Department of Defense. The contract calls for Acelrx to provide three thousand two hundred (3,200) boxes of the DSUVIA sufentanil nanoTab product to meet the minimum essential characteristics requested in the combined synopsis and solicitation from the U.S. Army Medical Materiel Development Activity. The solicitation sought the DSUVIA product to conduct a clinical trial under a one hundred percent (100%) small business set-aside. Performance will take place in Redwood City, California over a four-year period concluding in September 2024.
The contract award is associated with Solicitation Number W81XWH-20-R-0129 from the U.S. Army Medical Research Acquisition Activity and supports the Defense Health Agency's efforts to research and develop medical products for military personnel. No major subcontractors were indicated.
Quick answers
Who was awarded contract W81XWH20C0133?
W81XWH20C0133 was awarded to Acelrx Pharmaceuticals, Inc. by Defense Health Agency (Department of Defense) on September 20, 2020.
How much is contract W81XWH20C0133 worth?
The government has obligated $935,237 on W81XWH20C0133. Its potential value, with all options, is $3,570,235.
Was contract W81XWH20C0133 competed?
The extent of competition for W81XWH20C0133 was competed under sap. The government received 2 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award